Savara (SVRA) Return on Capital Employed (2011 - 2026)
Savara (SVRA) reported Return on Capital Employed of 60.41% for Q1 2026, down 271.0% year-over-year from 35.33% in Q1 2025, and up 13.57% on a QoQ basis from 69.89% in Q4 2025.
Savara (SVRA) has 16 years of Return on Capital Employed data on file, last reported at 60.41% in Q1 2026.
- Quarterly Return on Capital Employed fell 271.0% year-over-year to 60.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 60.41% (down 271.0% YoY) and the FY2025 annual result came in at 58.07%, down 90.0% from the prior year.
- Return on Capital Employed climbed to 60.41% in Q1 2026 per SVRA's latest filing, from 69.89% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.11% in Q2 2022 and bottomed at 89.47% in Q3 2025.
- The 5-year median for Return on Capital Employed is 44.5% (2024), against an average of 47.12%.
- The widest annual swing landed in 2022, when Return on Capital Employed surged 467 bps; it then sank 3866 bps in 2025.
- Tracing SVRA's Return on Capital Employed over 5 years: stood at 28.16% in 2022, then dropped by 26 bps to 35.46% in 2023, then sank by 38 bps to 48.88% in 2024, then plunged by 43 bps to 69.89% in 2025, then grew by 14 bps to 60.41% in 2026.
- Per Business Quant, the three latest SVRA Return on Capital Employed figures stand at 60.41% (Q1 2026), 69.89% (Q4 2025), and 89.47% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -60.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.41% |
| Dec 31, 2025 | -69.89% |
| Sep 30, 2025 | -89.47% |
| Jun 30, 2025 | -72.07% |
| Mar 31, 2025 | -57.69% |
| Dec 31, 2024 | -48.88% |
| Sep 30, 2024 | -50.81% |
| Jun 30, 2024 | -59.07% |
| Mar 31, 2024 | -44.50% |
| Dec 31, 2023 | -35.46% |
| Sep 30, 2023 | -37.50% |
| Jun 30, 2023 | -38.53% |
| Mar 31, 2023 | -33.09% |
| Dec 31, 2022 | -28.16% |
| Sep 30, 2022 | -26.24% |
| Jun 30, 2022 | -24.11% |
| Mar 31, 2022 | -25.22% |
| Dec 31, 2021 | -24.80% |
| Sep 30, 2021 | -24.20% |
| Jun 30, 2021 | -22.74% |
| Mar 31, 2021 | -29.88% |
| Dec 31, 2020 | -51.69% |
| Sep 30, 2020 | -64.81% |
| Jun 30, 2020 | -62.51% |
| Mar 31, 2020 | -68.42% |
| Dec 31, 2019 | -61.96% |
| Sep 30, 2019 | -44.78% |
| Jun 30, 2019 | -44.04% |
| Mar 31, 2019 | -35.98% |
| Dec 31, 2018 | -47.83% |
| Sep 30, 2018 | -52.74% |
| Jun 30, 2018 | -51.65% |
| Mar 31, 2018 | -41.26% |
| Dec 31, 2017 | -22.48% |
| Sep 30, 2017 | -21.25% |
| Jun 30, 2017 | -34.68% |
| Mar 31, 2017 | -94.70% |
| Dec 31, 2016 | -35.24% |
| Sep 30, 2016 | -72.24% |
| Jun 30, 2016 | -98.59% |
| Mar 31, 2016 | -106.44% |
| Dec 31, 2015 | -110.43% |
| Sep 30, 2015 | -79.46% |
| Jun 30, 2015 | -71.65% |
| Mar 31, 2015 | -55.88% |
| Dec 31, 2014 | -53.34% |
| Sep 30, 2014 | -55.01% |
| Jun 30, 2014 | -45.42% |
| Mar 31, 2014 | -43.29% |
| Dec 31, 2013 | -40.94% |
| Sep 30, 2013 | -34.33% |
| Jun 30, 2013 | -35.74% |
| Mar 31, 2013 | -41.10% |
| Dec 31, 2012 | -33.47% |
| Sep 30, 2012 | -27.99% |
| Jun 30, 2012 | -26.97% |
| Mar 31, 2012 | -25.24% |
| Dec 31, 2011 | -25.96% |
| Sep 30, 2011 | -29.41% |